Sugi Predict

Sugi Predict / Compounds / SCHEMBL5889460

SCHEMBL5889460

SCHEMBL5889460

CCCn1c(C(=O)OCC)cc2cc([N+](=O)[O-])ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.53
▸ NOD2 Q9HC29 2/20 0.52
▸ NOD1 Q9Y239 2/20 0.52
▸ KMT2A Q03164 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ CRHBP P24387 1/20 0.48
▸ CRHR2 Q13324 1/20 0.48
▸ ELANE P08246 2/20 0.46
▸ CCR2 P41597 1/20 0.46
▸ AR P10275 2/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ TP53 P04637 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ F2 P00734 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ CTRB1 P17538 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23045520 0.93 MAPT (0.51) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL31383538 0.93 MAPT (0.51) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL16732758 0.91 MAPT (0.54) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL4196083 0.90 NOD2 (0.54) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL29463255 0.90 KMT2A (0.50) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL23045605 0.90 KMT2A (0.50) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL23045545 0.88 MAPT (0.48) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL29463225 0.88 MAPT (0.48) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL23045560 0.87 NOD2 (0.51) MAPTNOD2NOD1KMT2ASMN1; SMN2
SCHEMBL23045588 0.87 NOD2 (0.51) MAPTNOD2NOD1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same KUKJE PHARMA CO., LTD. (KR) 2025-11-11 — — US disclosed
CN-114302874-B Indole carboxamide derivatives and pharmaceutical compositions containing the same 国际药品株式会社 2025-02-25 — — CN disclosed
US-20230000821-A1 INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KUKJE PHARMA CO., LTD. (KR) 2023-01-05 — — US disclosed
EP-4023638-A1 INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kukje Pharma Co., Ltd. (KR) 2022-07-06 — — EP disclosed
CN-114302874-A Indole carboxamide derivatives and pharmaceutical compositions comprising same 国际药品株式会社 2022-04-08 — — CN disclosed
WO-2021040393-A1 INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 국제약품 주식회사 2021-03-04 — — WO disclosed
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases BAYER HEALTHCARE AG (DE) 2006-08-17 — — US disclosed
US-7064218-B2 Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2006-06-20 — — US disclosed
US-7045544-B2 Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2006-05-16 — — US disclosed
EP-1578418-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES Bayer HealthCare AG (DE) 2005-09-28 — — EP disclosed
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases BAYER HEALTHCARE AG (DE) 2005-02-17 — — US disclosed
WO-2004056768-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2004-07-08 — — WO disclosed
WO-2004056768-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2004-07-08 — — WO disclosed
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GLAXOSMITHKLINE LLC 2003-11-13 — — US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 — — WO disclosed
WO-2003028719-A1 SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2003-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465588-B2 Indole carboxamide derivative and pharmaceutical composition containing same PTGES, PTGES2, PTGS1 MAPT 304/4885NOD2 1824/4885NOD1 805/4885
US-20230000821-A1 INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME PTGES, PTGES2, PTGS1 MAPT 304/4885NOD2 1824/4885NOD1 805/4885
US-20060183753-A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases DCK, UROD, QDPR MAPT 2350/4885NOD2 4141/4885NOD1 4321/4885
US-20050038101-A1 Substituted 2 5-diamidoindoles as ece inhibitors for the treatment of cardiovascular diseases ECE1, ECE2, EDNRA MAPT 3259/4885NOD2 4457/4885NOD1 3989/4885
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity TYR, CYP51A1, ODC1 MAPT 3578/4885NOD2 18/4885NOD1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.